These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

330 related items for PubMed ID: 12412793

  • 1. Bisphosphonates and primary hyperparathyroidism.
    Rodan GA.
    J Bone Miner Res; 2002 Nov; 17 Suppl 2():N150-3. PubMed ID: 12412793
    [Abstract] [Full Text] [Related]

  • 2. Nitrogen-containing bisphosphonate mechanism of action.
    Reszka AA, Rodan GA.
    Mini Rev Med Chem; 2004 Sep; 4(7):711-9. PubMed ID: 15379639
    [Abstract] [Full Text] [Related]

  • 3. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates.
    Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ.
    J Pharmacol Exp Ther; 2001 Feb; 296(2):235-42. PubMed ID: 11160603
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Bisphosphonates, specific inhibitors of osteoclast function and a class of drugs for osteoporosis therapy.
    Li B, Ling Chau JF, Wang X, Leong WF.
    J Cell Biochem; 2011 May; 112(5):1229-42. PubMed ID: 21465521
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Identification of a bisphosphonate that inhibits isopentenyl diphosphate isomerase and farnesyl diphosphate synthase.
    Thompson K, Dunford JE, Ebetino FH, Rogers MJ.
    Biochem Biophys Res Commun; 2002 Jan 18; 290(2):869-73. PubMed ID: 11785983
    [Abstract] [Full Text] [Related]

  • 9. Clodronate in the medical management of hyperparathyroidism.
    Hamdy NA, Gray RE, McCloskey E, Galloway J, Rattenbury JM, Brown CB, Kanis JA.
    Bone; 1987 Jan 18; 8 Suppl 1():S69-77. PubMed ID: 2961358
    [Abstract] [Full Text] [Related]

  • 10. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase.
    Bergstrom JD, Bostedor RG, Masarachia PJ, Reszka AA, Rodan G.
    Arch Biochem Biophys; 2000 Jan 01; 373(1):231-41. PubMed ID: 10620343
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy.
    Russell RG, Xia Z, Dunford JE, Oppermann U, Kwaasi A, Hulley PA, Kavanagh KL, Triffitt JT, Lundy MW, Phipps RJ, Barnett BL, Coxon FP, Rogers MJ, Watts NB, Ebetino FH.
    Ann N Y Acad Sci; 2007 Nov 01; 1117():209-57. PubMed ID: 18056045
    [Abstract] [Full Text] [Related]

  • 13. Mechanisms and treatment of hypercalcemia of malignancy.
    Clines GA.
    Curr Opin Endocrinol Diabetes Obes; 2011 Dec 01; 18(6):339-46. PubMed ID: 21897221
    [Abstract] [Full Text] [Related]

  • 14. [Bisphosphonates: the molecular targets and mechanisms of action].
    Wada S, Kamiya S, Ono K.
    Clin Calcium; 2005 May 01; 15(5):819-24. PubMed ID: 15876745
    [Abstract] [Full Text] [Related]

  • 15. Bisphosphonates: an overview with special reference to alendronate.
    Vasikaran SD.
    Ann Clin Biochem; 2001 Nov 01; 38(Pt 6):608-23. PubMed ID: 11732644
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Development of bisphosphonates].
    Nakatsuka K.
    Nihon Rinsho; 2003 Feb 01; 61(2):219-25. PubMed ID: 12638211
    [Abstract] [Full Text] [Related]

  • 19. In vivo effects of bisphosphonates on the osteoclast mevalonate pathway.
    Fisher JE, Rodan GA, Reszka AA.
    Endocrinology; 2000 Dec 01; 141(12):4793-6. PubMed ID: 11108295
    [Abstract] [Full Text] [Related]

  • 20. Hyperparathyroidism.
    Rude RK.
    Otolaryngol Clin North Am; 1996 Aug 01; 29(4):663-79. PubMed ID: 8844736
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.